PTPN11 and neoplasm: GDC-0623 (30 mg/kg, daily, orally) significantly reduced the growth of SHP2-silenced B16F10 tumors at different time points after inoculation of the SHP2-silenced tumor cells and, to a smaller, insignificant degree, the growth of control (p-LKO) tumors (2-way ANOVA for multiple comparisons; Figure 9, A, C, and E).